For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex 2010 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the U.S. Securities and Exchange Commission.
About CambrexCambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. We offer Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com. CAMBREX CORPORATIONStatements of Profit and LossFor the Quarters Ended September 30, 2011 and 2010(in thousands, except per-share data)20112010% of% ofAmountSalesAmountSalesGross Sales
49,356Commissions, Allowances and Rebates412492Net Sales57,79148,864Other1,364(1,090)Net Revenues59,15547,774Cost of Goods Sold41,32671.0%33,66468.2%Gross Profit17,82930.6%14,11028.6%Operating ExpensesSelling, General and Administrative Expenses9,81816.9%7,87916.0%Research and Development Expenses2,6154.5%3,0806.2%Restructuring Expenses--1,1872.4%Merger and Acquisition Expenses--7111.4%Total Operating Expenses12,43321.4%12,85726.0%Operating Profit5,3969.3%1,2532.5%Other Expenses:Interest Expense, net5641,233Other Expenses, net1452Equity in Losses of Partially-Owned Affiliate497-Income/(Loss) Before Income Taxes4,3217.4%(32)-0.1%Provision for Income Taxes1,
|SOURCE Cambrex Corporation|
Copyright©2010 PR Newswire.
All rights reserved